America's Best Nonprofits
  1. Home
  2. Health Care
  3. Beaverton, OR
  4. Answer2cancer

Answer2cancer

  • Beaverton, OR
  • Tax-exempt since 2017
  • EIN: 81-4885713
answer2cancer.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate

Organization summary

Answer2cancer is a 501(c)(3) organization, classified under Health Care (NTEE E70). Contributions are tax-deductible.

7299 Sw Linette Way, Beaverton, OR 97007-5099

In fiscal year 2025 it reported $1 in revenue and $10,388 in expenses, with contributions making up 0.0% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

Description;Amount^Spotify;204|Advocacy Day;48|Computer Tech Nial;252|Web Domains 2024;3269|Web Domains 2025;532|Computer and Misc Subscriptions;4213|Annual Filing Fee State of Oregon;70^Total;8588^

Largest programs · fiscal year 2025

  • In 2018, we held Answer2Cancer, Inc. full day event to bring resources, support and education at no charge to Portland, Oregon area cancer patients, their families and caregivers. Nearly 300 people attended the April 7, 2018 event. We also made presentations to community and health groups including Portland Oncology Pharmeceutical Society's leadership team. Additionally, we traveled to and began p… Read more

    In 2018, we held Answer2Cancer, Inc. full day event to bring resources, support and education at no charge to Portland, Oregon area cancer patients, their families and caregivers. Nearly 300 people attended the April 7, 2018 event. We also made presentations to community and health groups including Portland Oncology Pharmeceutical Society's leadership team. Additionally, we traveled to and began planning for 2019 and 2020 events in Bellingham, Spokane and the Tri-Cities, Washington. The 2020 event due to COVID-19, was held through an on-line format to reach those who were at higher risk due to suppressed immune systems. The event was held on October 3, 2020 and was title "Answer2Cancer Digital 2020" The event was attended by approximately 275 on-line attendees. In 2021, the focus of the year was education and outreach planning for events in 2022 and 2023.

  • Activities and planning 2022-responded and wrote two small Advocacy grants to Pfizer and also applied for Advocate grant from PhRMA. In, October of 2022 traveled to Missoula and Billings Montana regarding the possibility of bringing the A2C program to MT in 2023. Received a favorable reception at both locations from representatives of Johnson & Johnson and the American Cancer Society's Cancer Acti… Read more

    Activities and planning 2022-responded and wrote two small Advocacy grants to Pfizer and also applied for Advocate grant from PhRMA. In, October of 2022 traveled to Missoula and Billings Montana regarding the possibility of bringing the A2C program to MT in 2023. Received a favorable reception at both locations from representatives of Johnson & Johnson and the American Cancer Society's Cancer Action Network local director. Following up with Community Cancer Centers In MT and other organizations to begin the process for a summer 2023 event. In October of 2022, also traveled to Boise, ID meeting with a clinical trial specialist who is affiliated with a large health care system there at St. Luke's.

  • In 2023, we continued planning for 2024 patient education and support events in Eugene, Billings Montana and Boise Idaho. We worked closely with therapeutical companies to engage in patient education efforts with local health providers, policymakers and patient advocate organizations, to improve access to medicines for the underserved.
  • A2C was invited to submit an Advocacy grant to Pfizer, which was funded at $10,000. Funds are being used on a digital media to support/increase awareness of a national patient survey to determine drug cost variables for patients and families. For 2025, working on a pitch for an A2C event in Eugene, in cooperation with the Willamette Valley Cancer institute in Eugene and throughout Lane County
  • 2025-Challenging year of reaching out to make deeper partnerships, attended Advocacy Day in Salem. Seeking viable sponsors for 2026 events. Pharmaceutical companies are changing their models and it is more difficult to obtain partnerships for events and programs. Cuts to Federal funding and stronger competition for dollars is creating a challenging environment. The Focus for this year was to devel… Read more

    2025-Challenging year of reaching out to make deeper partnerships, attended Advocacy Day in Salem. Seeking viable sponsors for 2026 events. Pharmaceutical companies are changing their models and it is more difficult to obtain partnerships for events and programs. Cuts to Federal funding and stronger competition for dollars is creating a challenging environment. The Focus for this year was to develop relationships with partners for smaller events with smaller costs and larger impact. These take time to develop and move through the process. In 2025 A2C was invited to participate in the Advocacy activities with Vertex at the Oregon Capitol in March of 2025. Goal for 2026 is focused on a potential partnership and A2C event in Eugene, in cooperation with the Salem Cancer Community, Oregon Oncology Specialists and Willamette Valley Cancer Institute in Eugene/Lane County.

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$1Fiscal year 20252021: $9,14420212022: $7,80020222025: $12025
Expenses$10,388Fiscal year 20252021: $3,05920212022: $6,22520222025: $10,3882025
Total assets—Fiscal year 20252022: $31,0862022
Total liabilities—Fiscal year 20252022: $10,5222022
Fiscal year ending December 2025
Revenue$1
Expenses$10,388
Net income−$10,387
Net assets$15,983

Notable sources of revenue

Percent of total revenue
Contributions$0
Program services$0
Investment income$1
Other (net)$0

Assets / debt

Total assets—
Total liabilities—
Net assets$15,983

Compensation

Not in our extract for this year.

Fiscal year ending December 2022
Revenue$7,800
Expenses$6,225
Net income$1,575
Net assets$20,564

Notable sources of revenue

Percent of total revenue
Contributions$7,799
Program services$0
Investment income$1
Other (net)$0

Assets / debt

Total assets$31,086
Total liabilities$10,522
Net assets$20,564

Compensation

Not in our extract for this year.

Fiscal year ending December 2021
Revenue$9,144
Expenses$3,059
Net income$6,085
Net assets$13,002

Notable sources of revenue

Percent of total revenue
Contributions$9,142
Program services$0
Investment income$2
Other (net)$0

Assets / debt

Total assets—
Total liabilities—
Net assets$13,002

Compensation

Not in our extract for this year.

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?